SIRT6: A Drug Target and Biomarker for Aging and age-related Diseases

Target Name: SIRT6

NCBI ID: G51548

SIRT6

SIRT6: A Drug Target and Biomarker for Aging and age-related Diseases

Sirtuin 6 (SIRT6) is a natural compound found in various organisms, including bacteria, yeast, and animals. It has been studied extensively for its potential health benefits and its status as a drug target or biomarker for aging and age-related diseases. In this article, we will explore the science behind SIRT6 and its potential as a drug target and biomarker.

The Aging Process

Ageing is a natural process that occurs in all living organisms. As we age, our bodies undergo a range of changes that can lead to a range of age-related diseases, including heart disease, stroke, diabetes, and Alzheimer's disease. These diseases are caused by a combination of genetic and environmental factors, including inflammation, oxidative stress, and metabolic imbalances.

One of the key factors in the ageing process is the damage caused by oxidative stress. Oxidative stress occurs when the body's cells are exposed to harmful substances, such as free radicals, which can cause damage to cells and contribute to the development of age-related diseases.

SIRT6 as a Drug Target

SIRT6 has been shown to have a range of potential health benefits, including its ability to reduce oxidative stress and protect against age-related diseases. SIRT6 is a NAD+-dependent enzyme that is involved in a variety of cellular processes, including DNA repair, metabolism, and inflammation.

SIRT6 has been shown to have a positive impact on cellular health by its ability to reduce oxidative stress and protect against a range of age-related diseases. For example, studies have shown that SIRT6 can help protect against neurodegenerative diseases, such as Alzheimer's disease, by reducing the formation of toxic oxygen species that can cause damage to brain cells.

SIRT6 has also been shown to have a positive impact on cardiovascular health by reducing inflammation and improving blood flow. This can help to reduce the risk of heart disease and stroke, which are two of the leading causes of death in adults.

SIRT6 as a Biomarker

SIRT6 has also been shown to be a potential biomarker for age-related diseases. As we age, our bodies produce less SIRT6, which can make it a useful indicator of our overall health and the risk of age-related diseases.

SIRT6 levels have been shown to be lower in individuals who are older, and this has been associated with an increased risk of age-related diseases. For example, studies have shown that individuals who have higher SIRT6 levels are less likely to develop heart disease or stroke than those who have lower SIRT6 levels.

SIRT6 has also been shown to be a potential biomarker for age-related diseases by its ability to predict the risk of disease in individuals. For example, studies have shown that by measuring SIRT6 levels, researchers can predict the risk of neurodegenerative diseases, such as Alzheimer's disease, in individuals.

Conclusion

SIRT6 is a natural compound that has been shown to have a range of potential health benefits, including its ability to reduce oxidative stress and protect against age-related diseases. Its potential as a drug target or biomarker for aging and age-related diseases makes it an attractive area of research for further study. As research continues to advance, we may find new and innovative ways to use SIRT6 to improve human health and prevent age-related diseases.

Protein Name: Sirtuin 6

Functions: NAD-dependent protein deacetylase, deacylase and mono-ADP-ribosyltransferase that plays an essential role in DNA damage repair, telomere maintenance, metabolic homeostasis, inflammation, tumorigenesis and aging (PubMed:18337721, PubMed:19135889, PubMed:19625767, PubMed:21680843, PubMed:23217706, PubMed:23653361, PubMed:24052263, PubMed:27322069, PubMed:27180906, PubMed:21362626, PubMed:23552949, PubMed:30374165, PubMed:29555651). Displays protein-lysine deacetylase or defatty-acylase (demyristoylase and depalmitoylase) activity, depending on the context (PubMed:24052263, PubMed:27322069, PubMed:23552949). Acts as a key histone deacetylase by catalyzing deacetylation of histone H3 at 'Lys-9', 'Lys-18' and 'Lys-56' (H3K9ac, H3K18ac and H3K56ac, respectively), suppressing target gene expression of several transcription factors, including NF-kappa-B (PubMed:19625767, PubMed:24012758, PubMed:23892288, PubMed:23911928, PubMed:27043296, PubMed:26898756, PubMed:27180906, PubMed:33067423, PubMed:21362626, PubMed:30374165, PubMed:26456828). Acts as an inhibitor of transcription elongation by mediating deacetylation of H3K9ac and H3K56ac, preventing release of NELFE from chromatin and causing transcriptional pausing (By similarity). Involved in DNA repair by promoting double-strand break (DSB) repair: acts as a DSB sensor by recognizing and binding DSB sites, leading to (1) recruitment of DNA repair proteins, such as SMARCA5/SNF2H, and (2) deacetylation of histone H3K9ac and H3K56ac (PubMed:23911928, PubMed:31995034, PubMed:32538779). SIRT6 participation to DSB repair is probably involved in extension of life span (By similarity). Also promotes DNA repair by deacetylating non-histone proteins, such as DDB2 and p53/TP53 (PubMed:32789493, PubMed:29474172). Specifically deacetylates H3K18ac at pericentric heterochromatin, thereby maintaining pericentric heterochromatin silencing at centromeres and protecting against genomic instability and cellular senescence (PubMed:27043296). Involved in telomere maintenance by catalyzing deacetylation of histone H3 in telomeric chromatin, regulating telomere position effect and telomere movement in response to DNA damage (PubMed:18337721, PubMed:19625767, PubMed:21847107). Required for embryonic stem cell differentiation by mediating histone deacetylation of H3K9ac (PubMed:25915124, PubMed:29555651). Plays a major role in metabolism by regulating processes such as glycolysis, gluconeogenesis, insulin secretion and lipid metabolism (PubMed:24012758, PubMed:26787900). Inhibits glycolysis via histone deacetylase activity and by acting as a corepressor of the transcription factor HIF1A, thereby controlling the expression of multiple glycolytic genes (By similarity). Has tumor suppressor activity by repressing glycolysis, thereby inhibiting the Warburg effect (PubMed:23217706). Also regulates glycolysis and tumorigenesis by mediating deacetylation and nuclear export of non-histone proteins, such as isoform M2 of PKM (PKM2) (PubMed:26787900). Acts as a negative regulator of gluconeogenesis by mediating deacetylation of non-histone proteins, such as FOXO1 and KAT2A/GCN5 (PubMed:23142079, PubMed:25009184). Promotes beta-oxidation of fatty acids during fasting by catalyzing deacetylation of NCOA2, inducing coactivation of PPARA (By similarity). Acts as a regulator of lipid catabolism in brown adipocytes, both by catalyzing deacetylation of histones and non-histone proteins, such as FOXO1 (By similarity). Also acts as a regulator of circadian rhythms, both by regulating expression of clock-controlled genes involved in lipid and carbohydrate metabolism, and by catalyzing deacetylation of PER2 (By similarity). The defatty-acylase activity is specifically involved in regulation of protein secretion (PubMed:24052263, PubMed:23552949, PubMed:27322069, PubMed:28406396). Has high activity toward long-chain fatty acyl groups and mediates protein-lysine demyristoylation and depalmitoylation of target proteins, such as RRAS2 and TNF, thereby regulating their secretion (PubMed:23552949, PubMed:28406396). Also acts as a mono-ADP-ribosyltransferase by mediating mono-ADP-ribosylation of PARP1, TRIM28/KAP1 or SMARCC2/BAF170 (PubMed:21680843, PubMed:22753495, PubMed:27568560, PubMed:27322069). Mono-ADP-ribosyltransferase activity is involved in DNA repair, cellular senescence, repression of LINE-1 retrotransposon elements and regulation of transcription (PubMed:21680843, PubMed:22753495, PubMed:27568560)

The "SIRT6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIRT6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets